Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the efficacy and safety of anlotinib in patients with stage IV extranodal natural killer/T-cell lymphoma, nasal type.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
NCT06376721 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma
NCT05058755 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
NCT03630731 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
NCT03623087 · Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin T-cell Lymphoma, and more
NCT03107962 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Xinhua Hospital
Shanghai
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions